152 related articles for article (PubMed ID: 11053083)
1. Efficacy and toxicity of old and new disease modifying antirheumatic drugs.
Tugwell P; Welch V; Suarez-Almazor M; Shea B; Wells G
Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i32-5. PubMed ID: 11053083
[No Abstract] [Full Text] [Related]
2. A clinical and economic review of disease-modifying antirheumatic drugs.
Gabriel SE; Coyle D; Moreland LW
Pharmacoeconomics; 2001; 19(7):715-28. PubMed ID: 11548909
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
Nandi P; Kingsley GH; Scott DL
Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
[TBL] [Abstract][Full Text] [Related]
5. [Rheumatoid arthritis: milestones in classification and treatment].
Fiehn C
Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
[No Abstract] [Full Text] [Related]
7. Outstanding issues in use of disease-modifying agents in rheumatoid arthritis.
Madhok R; Capell HA
Lancet; 1999 Jan; 353(9149):257-8. PubMed ID: 9929016
[No Abstract] [Full Text] [Related]
8. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
Ranganathan P; Eisen S; Yokoyama WM; McLeod HL
Ann Rheum Dis; 2003 Jan; 62(1):4-9. PubMed ID: 12480661
[TBL] [Abstract][Full Text] [Related]
9. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
Feely MG; O'Dell JR
Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
[TBL] [Abstract][Full Text] [Related]
10. Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.
Barton P
Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv32-iv38. PubMed ID: 21859704
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
[TBL] [Abstract][Full Text] [Related]
12. Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
Kremer J
Arthritis Rheum; 2005 Oct; 53(5):636-8. PubMed ID: 16208649
[No Abstract] [Full Text] [Related]
13. Disappointing longterm result with disease modifying antirheumatic drugs.
Marubini E
J Rheumatol; 2001 Jan; 28(1):215. PubMed ID: 11196530
[No Abstract] [Full Text] [Related]
14. Rheumatoid arthritis management options for 2012.
Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):355. PubMed ID: 23091829
[No Abstract] [Full Text] [Related]
15. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.
Chakravarty K; McDonald H; Pullar T; Taggart A; Chalmers R; Oliver S; Mooney J; Somerville M; Bosworth A; Kennedy T; ;
Rheumatology (Oxford); 2008 Jun; 47(6):924-5. PubMed ID: 16940305
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
Castrejón I; Gibson KA; Pincus T
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
[TBL] [Abstract][Full Text] [Related]
17. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
Choy EH; Smith C; Doré CJ; Scott DL
Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
[TBL] [Abstract][Full Text] [Related]
19. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
20. [New basic therapeutic drugs from the viewpoint of evidence-based therapy].
Schattenkirchner M
Z Rheumatol; 2001 Dec; 60(6):473-6. PubMed ID: 11826744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
